Open AccessAntiarrhythmic effect of vernakalant in an experimental model of Long-QT-syndrome
Author(s) -
Gerrit Frommeyer,
C. Clauss,
Christian Ellermann,
Harilaos Bogossian,
Dirk G. Dechering,
Simon Kochhäuser,
Florian Reinke,
Christian Pott,
Lars Eckardt
Publication year - 2016
Publication title -
ep europace
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.119
H-Index - 102
eISSN - 1532-2092
pISSN - 1099-5129
DOI - 10.1093/europace/euw182
Subject(s) - veratridine , medicine , repolarization , afterdepolarization , cardiology , erythromycin , qt interval , anesthesia , electrophysiology , pharmacology , sodium channel , sodium , chemistry , organic chemistry , biochemistry , antibiotics
The antiarrhythmic drug vernakalant exerts antiarrhythmic effects in atrial fibrillation. Recent experimental data suggest interactions with the late sodium current and antiarrhythmic effects in ventricular arrhythmias. We aimed at investigating whether treatment with vernakalant reduces polymorphic ventricular tachycardia (VT) in an experimental model of Long-QT-syndrome (LQTS).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom